

A targeted literature review exploring solutions for inclusivity of transgender and non-binary patients in clinical research

Rosamund Round,^a Nichola Gokool,^b Georgiana Manica,^c Liam Paschall,^d Simon Foulcer^b

^aParexel International, Uxbridge, Middlesex, UK; ^bParexel International, Worthing, West Sussex, UK;

^cParexel International, Bucharest, Romania; ^dParexel International, Durham, NC, USA

Presented at: DIA Global Annual Meeting, June 19-23, 2022, Chicago, IL. P109.

Full list of identified literature

1. Clinical trials

1.1 Transgender as a specific population

1. Gillard S, Bremner S, Patel A, et al. Peer support for discharge from inpatient mental health care versus care as usual in England (ENRICH): a parallel, two-group, individually randomised controlled trial. *Lancet Psychiatry*. 2022;9(2):125-136. [https://doi.org/10.1016/S2215-0366\(21\)00398-9](https://doi.org/10.1016/S2215-0366(21)00398-9)
2. Huang Y, Naidoo L, Zhang L, et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. *EBioMedicine*. 2021;64:103203. <https://doi.org/10.1016/j.ebiom.2020.103203>
3. Kapadia SN, Wu C, Mayer KH, et al. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. *PLoS One*. 2018;13(12):e0206577. <https://doi.org/10.1371/journal.pone.0206577>
4. Mujugira A, Nakyanzi A, Kasiita V, et al. HIV self-testing and oral pre-exposure prophylaxis are empowering for sex workers and their intimate partners: a qualitative study in Uganda. *J Int AIDS Soc*. 2021;24(9):e25782. <https://doi.org/10.1002/jia2.25782>
5. Uhrig Castonguay BJ, Cressman AE, Kuo I, et al. The implementation of a text messaging intervention to improve HIV continuum of care outcomes among persons recently released from correctional facilities: randomized controlled trial. *JMIR Mhealth Uhealth*. 2020;8(2):e16220. doi: 10.2196/16220
6. Waldo KAM, Hayes M, Watt PW, Maxwell NS. Physiological and perceptual responses in the elderly to simulated daily living activities in UK summer climatic conditions. *Public Health*. 2018;161:163-170. <https://doi.org/10.1016/j.puhe.2018.04.012>
7. Wiley DJ, Hsu HK, Ganser MA, et al. Cholinergic modulation of exposure disrupts hippocampal processes and augments extinction: proof-of-concept study with social anxiety disorder. *Biol Psychiatry*. 2019;86(9):703-711. <https://doi.org/10.1016/j.biopsych.2019.04.012>

1.2 Transgender as a sexual minority

1. Anand T, Nitpolprasert C, Jantarapakde J, et al. Implementation and impact of a technology-based HIV risk-reduction intervention among Thai men who have sex with men using "Vialogues": a randomized controlled trial. *AIDS Care*. 2020;32(3):394-405. doi: [10.1080/09540121.2019.1622638](https://doi.org/10.1080/09540121.2019.1622638)
2. Carballo-Diéguez A, Giguere R, Balán IC, et al. Few aggressive or violent incidents are associated with the use of HIV self-tests to screen sexual partners among key populations. *AIDS Behav*. 2020;24(7):2220-2226. doi: [10.1007/s10461-020-02809-1](https://doi.org/10.1007/s10461-020-02809-1)
3. Coffin PO, Santos GM, Hern J, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. *JAMA Psychiatry*. 2020;77(3):246-255. doi: [10.1001/jamapsychiatry.2019.3655](https://doi.org/10.1001/jamapsychiatry.2019.3655)
4. Colson PW, Franks J, Wu Y, et al. Adherence to pre-exposure prophylaxis in Black men who have sex with men and transgender women in a community setting in Harlem, NY. *AIDS Behav*. 2020;24(12):3436-3455. doi: [10.1007/s10461-020-02901-6](https://doi.org/10.1007/s10461-020-02901-6)
5. Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. *N Engl J Med*. 2021;384(11):1003-1014. doi: [10.1056/NEJMoa2031738](https://doi.org/10.1056/NEJMoa2031738)
6. Edupuganti S, Mgodini N, Karuna ST, et al. Feasibility and successful enrollment in a proof-of-concept HIV prevention trial of VRC01, a broadly neutralizing HIV-1 monoclonal antibody. *J Acquir Immune Defic Syndr*. 2021;87(1):671-679. doi: [10.1097/QAI.0000000000002639](https://doi.org/10.1097/QAI.0000000000002639)
7. Egan JE, Corey SL, Henderson ER, et al. Feasibility of a web-accessible game-based intervention aimed at improving help seeking and coping among sexual and gender minority youth: results from a randomized controlled trial. *J Adolesc Health*. 2021;69(4):604-614. doi: [10.1016/j.jadohealth.2021.03.027](https://doi.org/10.1016/j.jadohealth.2021.03.027)
8. Frye V, Nandi V, Hirshfield S, et al. Brief report: randomized controlled trial of an intervention to match young Black men and transwomen who have sex with men or transwomen to HIV testing options in New York City (All About Me). *J Acquir Immune Defic Syndr*. 2020;83(1):31-36. doi: [10.1097/QAI.0000000000002223](https://doi.org/10.1097/QAI.0000000000002223)
9. Glidden DV, Das M, Dunn DT, et al. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. *J Int AIDS Soc*. 2021;24(5):e25744. doi: [10.1002/jia2.25744](https://doi.org/10.1002/jia2.25744)
10. Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. *Clin Infect Dis*. 2018;67(3):411-419. doi: [10.1093/cid/ciy083](https://doi.org/10.1093/cid/ciy083)
11. Goldwirth L, Bauer R, Liegeon G, et al. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. *J Antimicrob Chemother*. 2021;76(10):2675-2680. doi: [10.1093/jac/dkab253](https://doi.org/10.1093/jac/dkab253)
12. Gonzales P, Grieco A, White E, et al. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. *PLoS One*. 2020;15(3):e0228433. doi: [10.1371/journal.pone.0228433](https://doi.org/10.1371/journal.pone.0228433)
13. Grant RM, Pellegrini M, Defechereux PA, et al. Sex hormone therapy and tenofovir diphosphate concentration in dried blood spots: primary results of the interactions between antiretrovirals and transgender hormones study. *Clin Infect Dis*. 2021;73(7):e2117-e2123. doi: [10.1093/cid/ciaa1160](https://doi.org/10.1093/cid/ciaa1160)
14. Hakim AJ, Coy K, Patnaik P, et al. An urgent need for HIV testing among men who have sex with men and transgender women in Bamako, Mali: low awareness of HIV infection and viral suppression among those living with HIV. *PLoS One*. 2018;13(11):e0207363. doi: [10.1371/journal.pone.0207363](https://doi.org/10.1371/journal.pone.0207363)

15. Hassan A, Wertheim JO, Blumenthal JS, et al. Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners. *Medicine (Baltimore)*. 2019;98(50):e18232. doi: [10.1097/MD.00000000000018232](https://doi.org/10.1097/MD.00000000000018232)
16. Holtz TH, Chitwarakorn A, Hughes JP, et al. HPTN 067/ADAPT: correlates of sex-related pre-exposure prophylaxis adherence, Thai men who have sex with men, and transgender women, 2012-2013. *J Acquir Immune Defic Syndr*. 2019;82(2):e18-e26. doi: [10.1097/QAI.0000000000002131](https://doi.org/10.1097/QAI.0000000000002131)
17. Iribarren S, Lentz C, Sheinfil AZ, et al. Using an HIV self-test kit to test a partner: attitudes and preferences among high-risk populations. *AIDS Behav*. 2020;24(11):3232-3243. doi: [10.1007/s10461-020-02885-3](https://doi.org/10.1007/s10461-020-02885-3)
18. Kuhns LM, Karnik N, Hotton A, et al. A randomized controlled efficacy trial of an electronic screening and brief intervention for alcohol misuse in adolescents and young adults vulnerable to HIV infection: step up, test up study protocol. *BMC Public Health*. 2020;20(1):30. doi: [10.1186/s12889-020-8154-6](https://doi.org/10.1186/s12889-020-8154-6)
19. Kuo I, Liu T, Patrick R, et al. Use of an mHealth intervention to improve engagement in HIV community-based care among persons recently released from a correctional facility in Washington, DC: a pilot study. *AIDS Behav*. 2019;23(4):1016-1031. doi: [10.1007/s10461-018-02389-1](https://doi.org/10.1007/s10461-018-02389-1)
20. Lama JR, Brezak A, Dobbins JG, et al. Design strategy of the sabes study: diagnosis and treatment of early HIV infection among men who have sex with men and transgender women in Lima, Peru, 2013-2017. *Am J Epidemiol*. 2018;187(8):1577-1585. doi: [10.1093/aje/kwy030](https://doi.org/10.1093/aje/kwy030)
21. Lama JR, Ignacio RAB, Alfaro R, et al. Clinical and immunologic outcomes after immediate or deferred antiretroviral therapy initiation during primary human immunodeficiency virus infection: the Sabes randomized clinical study. *Clin Infect Dis*. 2021;72(6):1042-1050. doi: [10.1093/cid/ciaa167](https://doi.org/10.1093/cid/ciaa167)
22. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. *N Engl J Med*. 2021;385(7):595-608. doi: [10.1056/NEJMoa2101016](https://doi.org/10.1056/NEJMoa2101016)
23. Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. *PLoS Med*. 2018;15(11):e1002690. doi: [10.1371/journal.pmed.1002690](https://doi.org/10.1371/journal.pmed.1002690)
24. Lazcano-Ponce E, Salmerón J, González A, et al. Prevention and control of neoplasms associated with HPV in high-risk groups in Mexico City: the Condesa study. *Salud Publica Mex*. 2018;60(6):703-712. doi: [10.21149/10034](https://doi.org/10.21149/10034)
25. Liu AY, Norwood A, Gundacker H, et al. Brief report: routine use of oral PrEP in a phase 2 rectal microbicide study of tenofovir reduced-glycerin 1% gel (MTN-017). *J Acquir Immune Defic Syndr*. 2019;81(5):516-520. doi: [10.1097/QAI.0000000000002066](https://doi.org/10.1097/QAI.0000000000002066)
26. Lee JGL, Blanchflower TM, O'Brien KF, et al. Assessing the potential impact of cigarette packs designed for lesbian, gay, bisexual, and transgender adults: a randomized experiment to inform U.S. regulation, 2018. *Health Promot Pract*. 2020;21(1_suppl):157S-164S. doi: [10.1177/1524839919879923](https://doi.org/10.1177/1524839919879923)
27. Lemos MP, Nandi V, Dragavon J, et al. HIV-1 nucleic acids identify rectal HIV exposures in self-collected rectal swabs, whereas Y-chromosome single tandem repeat mixtures are not reliable biomarkers of condomless receptive anal intercourse. *J Acquir Immune Defic Syndr*. 2021;88(2):138-148. doi: [10.1097/QAI.0000000000002748](https://doi.org/10.1097/QAI.0000000000002748)
28. Leu CS, Giguere R, Bauermeister JA, et al. Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men. *AIDS Care*. 2019;31(3):379-387. doi: [10.1080/09540121.2018.1533223](https://doi.org/10.1080/09540121.2018.1533223)

29. MacCarthy S, Izenberg M, Barreras JL, et al. Rapid mixed-methods assessment of COVID-19 impact on Latinx sexual minority men and Latinx transgender women. *PLoS One*. 2020;15(12):e0244421. doi: [10.1371/journal.pone.0244421](https://doi.org/10.1371/journal.pone.0244421)
30. Marins LMS, Torres TS, Leite IDC, et al. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: results from the PrEP Brasil study. *PLoS One*. 2019;14(8):e0221281. doi: [10.1371/journal.pone.0221281](https://doi.org/10.1371/journal.pone.0221281)
31. Matthews AK, Steffen AD, Kuhns LM, et al. Evaluation of a randomized clinical trial comparing the effectiveness of a culturally targeted and nontargeted smoking cessation intervention for lesbian, gay, bisexual, and transgender smokers. *Nicotine Tob Res*. 2019;21(11):1506-1516. doi: [10.1093/ntr/nty184](https://doi.org/10.1093/ntr/nty184)
32. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet*. 2020;396(10246):239-254. doi: [10.1016/S0140-6736\(20\)31065-5](https://doi.org/10.1016/S0140-6736(20)31065-5)
33. McGowan I, Wilkin T, Landovitz RJ, et al. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. *AIDS*. 2019;33(2):237-246. doi: [10.1097/QAD.0000000000002038](https://doi.org/10.1097/QAD.0000000000002038)
34. Mega ER. 'Mosaic' HIV vaccine to be tested in thousands of people across the world. *Nature*. 2019;572(7768):165-166. doi: [10.1038/d41586-019-02319-8](https://doi.org/10.1038/d41586-019-02319-8)
35. Mehrotra ML, Westreich D, McMahan VM, et al. Baseline characteristics explain differences in effectiveness of randomization to daily oral TDF/FTC PrEP between transgender women and cisgender men who have sex with men in the iPrEx trial. *J Acquir Immune Defic Syndr*. 2019;81(3):e94-e98. doi: [10.1097/QAI.0000000000002037](https://doi.org/10.1097/QAI.0000000000002037)
36. Montañó MA, Alfaro R, Ness T, et al. Sexual behavior and sexually transmitted infection outcomes among men who have sex with men and transgender women participating in a study of the timing of antiretroviral therapy in Lima, Peru. *Sex Transm Dis*. 2020;47(12):825-831. doi: [10.1097/OLQ.0000000000001310](https://doi.org/10.1097/OLQ.0000000000001310)
37. Neidich SD, Fong Y, Li SS, et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. *J Clin Invest*. 2019;129(11):4838-4849. doi: [10.1172/JCI126391](https://doi.org/10.1172/JCI126391)
38. Ogbuagu O, Ruane PJ, Podzamczar D, et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet HIV*. 2021;8(7):e397-e407. doi: [10.1016/S2352-3018\(21\)00071-0](https://doi.org/10.1016/S2352-3018(21)00071-0)
39. Pachankis JE, McConocha EM, Clark KA, et al. A transdiagnostic minority stress intervention for gender diverse sexual minority women's depression, anxiety, and unhealthy alcohol use: a randomized controlled trial. *J Consult Clin Psychol*. 2020;88(7):613-630. doi: [10.1037/ccp0000508](https://doi.org/10.1037/ccp0000508)
40. Passaro RC, Chávez-Gomez S, Castañeda-Huaripata A, et al. Personalized cognitive counseling reduces drinking expectancy among men who have sex with men and transgender women in Lima, Peru: a pilot randomized controlled trial. *AIDS Behav*. 2020;24(11):3205-3214. doi: [10.1007/s10461-020-02882-6](https://doi.org/10.1007/s10461-020-02882-6)
41. Philliber A. The IN-clued program: a randomized control trial of an effective sex education program for lesbian, gay, bisexual, transgender, queer, and questioning youths. *J Adolesc Health*. 2021;69(4):636-643. doi: [10.1016/j.jadohealth.2021.04.002](https://doi.org/10.1016/j.jadohealth.2021.04.002)
42. Pornpaisalsakul K, Songtaweasin WN, Tepmongkol S, et al. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis. *J Int AIDS Soc*. 2020;23(10):e25624. doi: [10.1002/jia2.25624](https://doi.org/10.1002/jia2.25624)

43. Songtaweessin WN, Kawichai S, Phanuphak N, et al. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial. *J Int AIDS Soc.* 2020;23(suppl 5):e25564. doi: [10.1002/jia2.25564](https://doi.org/10.1002/jia2.25564)
44. Shipherd JC, Darling JE, Klap RS, et al. Experiences in the Veterans Health Administration and impact on healthcare utilization: comparisons between LGBT and Non-LGBT women veterans. *LGBT Health.* 2018;5(5):303-311. doi: [10.1089/lgbt.2017.0179](https://doi.org/10.1089/lgbt.2017.0179)
45. Tan RKJ, Koh WL, Le D, et al. Effect of a web drama video series on HIV and other sexually transmitted infection testing among gay, bisexual and queer men: study protocol for a community-based, pragmatic randomised controlled trial in Singapore: the People Like Us (PLU) evaluation study. *BMJ Open.* 2020;10(4):e033855. doi: [10.1136/bmjopen-2019-033855](https://doi.org/10.1136/bmjopen-2019-033855)
46. Teixeira da Silva D, Bouris A, Ramachandran A, et al. Embedding a linkage to preexposure prophylaxis care intervention in social network strategy and partner notification services: results from a pilot randomized controlled trial. *J Acquir Immune Defic Syndr.* 2021;86(2):191-199. doi: [10.1097/QAI.0000000000002548](https://doi.org/10.1097/QAI.0000000000002548)
47. Wiley DJ, Hsu HK, Ganser MA, et al. Comparison of nylon-flocked swab and Dacron swab cytology for anal HSIL detection in transgender women and gay, bisexual, and other men who have sex with men. *Cancer Cytopathol.* 2019;127(4):247-257. doi: [10.1002/cncy.22114](https://doi.org/10.1002/cncy.22114)
48. Witzel TC, Bourne A, Burns FM, et al. HIV self-testing intervention experiences and kit usability: results from a qualitative study among men who have sex with men in the SELPHI (Self-Testing Public Health Intervention) randomized controlled trial in England and Wales. *HIV Med.* 2020;21(3):189-197. doi: [10.1111/hiv.12818](https://doi.org/10.1111/hiv.12818)
49. Witzel TC, Gabriel MM, McCabe L, et al. Pilot phase of an internet-based RCT of HIVST targeting MSM and transgender people in England and Wales: advertising strategies and acceptability of the intervention. *BMC Infect Dis.* 2019;19(1):699. doi: [10.1186/s12879-019-4247-1](https://doi.org/10.1186/s12879-019-4247-1)
50. Yellin H, Beckwith C, Kurth A, et al. Syndemic effect of mental illness and substance use on viral suppression among recently-incarcerated, HIV-infected individuals in the CARE+ Corrections study. *AIDS Care.* 2018;30(10):1252-1256. doi: [10.1080/09540121.2018.1455961](https://doi.org/10.1080/09540121.2018.1455961)

1.3 Transgender-specific interventions

1. Andrasik M, Grove D, Broder G, et al. Efficacy of an empowerment-based, group-delivered HIV prevention intervention for young transgender women: the Project LifeSkills randomized clinical trial. *Vaccine.* 2019;37(29):3911-3917. doi: [10.1016/j.vaccine.2019.05.016](https://doi.org/10.1016/j.vaccine.2019.05.016)
2. Budge SL, Sinnard MT, Hoyt WT. Longitudinal effects of psychotherapy with transgender and nonbinary clients: a randomized controlled pilot trial. *Psychotherapy (Chic).* 2021;58(1):1-11. doi: doi.org/10.1037/pst0000310
3. Burinkul S, Panyakhamlerd K, Suwan A, et al. Anti-androgenic effects comparison between cyproterone acetate and spironolactone in transgender women: a randomized controlled trial. *J Sex Med.* 2021;18(7):1299-1307. doi: doi.org/10.1016/j.jsxm.2021.05.003
4. Cirrincione LR, Podany AT, Havens JP, et al. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. *J Antimicrob Chemother.* 2020;75(5):1242-1249. <https://doi.org/10.1093/jac/dkaa016>
5. Clark J, Reisner S, Perez-Brumer A, et al. TransPrEP: results from the pilot study of a social network-based intervention to support PrEP adherence among transgender women in Lima, Peru. *AIDS Behav.* 2021;25(6):1873-1883. doi: [10.1007/s10461-020-03117-4](https://doi.org/10.1007/s10461-020-03117-4)

6. Damanpak-Rizi M, Farnam F, Khodakhah P. Effect of cognitive-behavioral therapy on domestic violence and its consequences in transgender youth: a randomized clinical trial, parallel group study. *BMC Psychiatry*. 2021;21(1):210. [doi: 10.1186/s12888-021-03224-z](https://doi.org/10.1186/s12888-021-03224-z)
7. Fauk NK, Merry MS, Putra S, et al. Perceptions among transgender women of factors associated with the access to HIV/AIDS-related health services in Yogyakarta, Indonesia. *PLoS One*. 2019;14(8):e0221013. <https://doi.org/10.1371/journal.pone.0221013>
8. Garofalo R, Kuhns LM, Reisner SL, et al. A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru. *JAMA Pediatr*. 2018;172(10):916-923. doi.org/10.1016/j.vaccine.2019.05.016
9. Jin H, Restar A, Goedel WC, et al. Maternal support is protective against suicidal ideation among a diverse cohort of young transgender women. *LGBT Health*. 2020 Oct;7(7):349-357. doi.org/10.1089/lgbt.2020.0219
10. Lacombe-Duncan A, Logie CH, Persad Y, et al. 'Transgender Education for Affirmative and Competent HIV and Healthcare (TEACHH)': protocol of community-based intervention development and a non-randomised multisite pilot study with pre-post test design in Canada. *BMJ Open*. 2020;10(7):e034144. [doi: 10.1136/bmjopen-2019-034144](https://doi.org/10.1136/bmjopen-2019-034144)
11. López de Lara D, Pérez Rodríguez O, Cuellar Flores I, et al. Psychosocial assessment in transgender adolescents. *An Pediatr*. 2020;93(1):41-48. <https://doi.org/10.1016/j.anpedi.2020.01.019>
12. Morrison SD, Capitán-Cañadas F, Sánchez-García A, et al. Prospective quality-of-life outcomes after facial feminization surgery: an international multicenter study. *Plast Reconstr Surg*. 2020;145(6):1499-1509. [doi: 10.1097/PRS.00000000000006837](https://doi.org/10.1097/PRS.00000000000006837)
13. Perl L, Elkon-Tamir E, Segev-Becker A, et al. Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study. *J Pediatr Endocrinol Metab*. 2021;34(6):741-745. doi.org/10.1515/jpem-2021-0172
14. Restar AJ, Jin H, Ogunbajo A, et al. Prevalence and risk factors on nonmedical prescription opioid use among transgender girls and young women. *JAMA Netw Open*. 2020;3(3):e201015. [doi: 10.1001/jamanetworkopen.2020.1015](https://doi.org/10.1001/jamanetworkopen.2020.1015)
15. Saul H, Gursul D. Self-testing for HIV could increase diagnoses in the trans community. *BMJ*. 2021;375:n2633. doi.org/10.1136/bmj.n2633
16. Schlosshauer T, Kiehlmann M, Riener MO, et al. Effect of low-thermal dissection device versus conventional electrocautery in mastectomy for female-to-male transgender patients. *Int Wound J*. 2020;17(5):1239-1245. doi.org/10.1111/iwj.13382
17. Smeaton LM, Kileel EM, Grinsztejn B, et al. Characteristics of REPRIEVE trial participants identifying across the transgender spectrum. *J Infect Dis*. 2020;222(suppl 1):S31-S40. doi.org/10.1093/infdis/jiaa213
18. Stephenson R, Todd K, Kahle E, et al. Project Moxie: results of a feasibility study of a telehealth intervention to increase HIV testing among binary and nonbinary transgender youth. *AIDS Behav*. 2020;24(5):1517-1530. [doi: 10.1007/s10461-019-02741-z](https://doi.org/10.1007/s10461-019-02741-z)
19. Timmermans FW, Mokken SE, Smit JM, et al. Within-patient randomized clinical trial comparing incisional negative-pressure wound therapy with suction drains in gender-affirming mastectomies. *Br J Surg*. 2021;108(8):925-933. doi.org/10.1093/bjs/znab204

20. Vanaman ME, Chapman HA. Disgust and disgust-driven moral concerns predict support for restrictions on transgender bathroom access. *Politics Life Sci.* 2020;39(2):200-214. doi.org/10.1017/pls.2020.20
21. Vlot MC, Wiepjes CM, de Jongh RT, et al. Gender-affirming hormone treatment decreases bone turnover in transwomen and older transmen. *J Bone Miner Res.* 2019;34(10):1862-1872. doi.org/10.1002/jbmr.3762

2. Barriers to clinical trial inclusion of transgender and non-binary patients – targeted search

1. Blotner C, Rajunov M. Engaging transgender patients: using social media to inform medical practice and research in transgender health. *Transgender Health.* 2018;3(1):225-228. doi.org/10.1089/trgh.2017.0039
2. Cargill VA. Valuing the vulnerable - the important role of transgender communities in biomedical research. *Ethn Dis.* 2020;30(2):247-250. doi.org/10.18865/ed.30.2.247
3. Chen B, Jin H, Yang Z, et al. An approach for transgender population information extraction and summarization from clinical trial text. *BMC Medical Inform.* 2019;19(suppl 2):62. doi.org/10.1186/s12911-019-0768-1
4. Cirrincione LR, Huang KJ. Sex and gender differences in clinical pharmacology: implications for transgender medicine. *Clin Pharmacol Ther.* 2021;110(4):897-908. doi.org/10.1002/cpt.2234
5. DuBois LZ, Gibb JK, Juster RP, et al. Biocultural approaches to transgender and gender diverse experience and health: integrating biomarkers and advancing gender/sex research. *Am J Hum Biol.* 2021;33(1): e23555. doi.org/10.1002/ajhb.23555
6. Geist C, Greenberg KB, Luikenaar RAC, et al. Pediatric research and health care for transgender and gender diverse adolescents and young adults: improving (biopsychosocial) health outcomes. *Acad Pediatr.* 2021;21(1):32-42. doi.org/10.1016/j.acap.2020.09.010
7. Gerth J, Becerra-Culqui T, Bradlyn A, et al. Agreement between medical records and self-reports: implications for transgender health research. *Rev Endocr Metab Disord.* 2018;19(3):263-269. doi.org/10.1007/s11154-018-9461-4
8. Ghorbanian A, Aiello B, Staples J. Under-representation of transgender identities in research: the limitations of traditional quantitative survey data. *Transgender Health.* 2021. doi.org/10.1089/trgh.2020.0107
9. Henderson ER, Blosnich JR, Herman JL, et al. Considerations on sampling in transgender health disparities research. *LGBT Health.* 2019;6(6):267-270. doi.org/10.1089/lgbt.2019.0069
10. Jones NC, Reyes ME, Quinn GP, et al. Survey of principal investigators in biobanking: knowledge, attitudes, and research behaviors about transgender and gender-diverse patients. *JCO Oncol.* 2020;16(10):e1192-e1201. doi.org/10.1200/OP.20.00193
11. Linsenmeyer W, Waters J. Sex and gender differences in nutrition research: considerations with the transgender and gender nonconforming population. *J Nutr.* 2021;20(1):6. doi.org/10.1186/s12937-021-00662-z

12. Marshall Z, Welch V, Minichiello A, et al. Documenting research with transgender, nonbinary, and other gender diverse (trans) individuals and communities: introducing the global trans research evidence map. *Transgender Health*. 2019;4(1):68-80. doi.org/10.1089/trgh.2018.0020
13. Moseson H, Zazanis N, Goldberg E, et al. The imperative for transgender and gender nonbinary inclusion: beyond women's health. *Obstet Gynecol*. 2020;135(5):1059-1068. doi.org/10.1097/AOG.00000000000003816
14. Poteat T, Aqil A, Corbett D, et al. "I would really want to know that they had my back": transgender women's perceptions of HIV cure-related research in the United States. *PloS One*. 2020;15(12):e0244490. doi.org/10.1371/journal.pone.0244490
15. Reardon S. The largest study involving transgender people is providing long-sought insights about their health. *Nature*. 2019;568(7753):446-449. doi.org/10.1038/d41586-019-01237-z
16. Rich AJ, Poteat T, Koehoorn M, et al. Development of a computable phenotype to identify a transgender sample for health research purposes: a feasibility study in a large linked provincial healthcare administrative cohort in British Columbia, Canada. *BMJ Open*. 2021;11(3):e040928. doi.org/10.1136/bmjopen-2020-040928
17. Safer JD. Research gaps in medical treatment of transgender/nonbinary people. *J Clin Invest*. 2021;131(4):e142029. doi.org/10.1172/JCI142029
18. Salk RH, Thoma BC, Choukas-Bradley S. The gender minority youth study: overview of methods and social media recruitment of a nationwide sample of U.S. cisgender and transgender adolescents. *Arch Sex Behav*. 2020;49(7):2601-2610. doi.org/10.1007/s10508-020-01695-x
19. Siskind R, Collins C, Campbell R, et al. Fostering transgender inclusion in HIV prevention research. *J Int AIDS Soc*. 2021;24(suppl. 1):PU05.01. <https://programme.hivr4p.org/Abstract/Abstract/376?msclid=33b9bfcccd3311ecadf36e3012cba1d9>
20. Staples JM, Bird ER, Masters TN, et al. Considerations for culturally sensitive research with transgender adults: a qualitative analysis. *J Sex Res*. 2018;55(8):1065-1076. doi.org/10.1080/00224499.2017.1292419
21. Theisen JG, Amarillo IE. Creating affirmative and inclusive practices when providing genetic and genomic diagnostic and research services to gender-expansive and transgender patients. *JALM*. 2021;6(1):142-154. doi.org/10.1093/jalm/ifa165
22. Ware J. Research topics inhibited by transgender paradigm. *Arch Sex Behav*. 2020;49(7):2237-2238. doi.org/10.1007/s10508-020-01758-z
23. Xie F, Getahun D, Quinn VP, et al. An automated algorithm using free-text clinical notes to improve identification of transgender people. *Inform Health Soc Care*. 2021;46(1):18-28. doi.org/10.1080/17538157.2020.1828890

3. Healthcare access for transgender and non-binary patients

3.1 Reported barriers

1. Cahill SR, Keatley J, Wade TS, et al. "Some of us, we don't know where we're going to be tomorrow." Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. *AIDS Care*. 2020;32(5):585-593. doi.org/10.1080/09540121.2019.1659912
2. DeJonckheere M, Zhao A, Lane J, et al. Results of a national text message poll of youth: perspectives on primary care. *J Adolesc Health*. 2020;67(6):814-820. doi.org/10.1016/j.jadohealth.2020.04.017
3. Feldman JL, Luhur WE, Herman JL, et al. Health and health care access in the US transgender population health (TransPop) survey. *Andrology*. 2021;9(6):1707-1718. doi.org/10.1111/andr.13052
4. Kattari SK, Atteberry-Ash B, Kinney MK, et al. One size does not fit all: differential transgender health experiences. *Health Soc Work*. 2019;58(9):899-917. doi.org/10.1080/00981389.2019.1677279
5. Kearns S, Kroll T, O'Shea D, et al. Experiences of transgender and non-binary youth accessing gender-affirming care: a systematic review and meta-ethnography. *PloS One*. 2021;16(9):e0257194. doi.org/10.1371/journal.pone.0257194
6. Rahman M, Li DH, Moskowitz DA. Comparing the healthcare utilization and engagement in a sample of transgender and cisgender bisexual+ persons. *Arch Sex Behav*. 2019;48(1):255-260. [doi: 10.1007/s10508-018-1164-0](https://doi.org/10.1007/s10508-018-1164-0)
7. Renner J, Täuber L, Nieder TO. Need for inclusive consideration of transgender and gender diverse people in e-health services: a systematic review. *J Clin Med*. 2020;11(4):1090. doi.org/10.3390/jcm11041090
8. Romanelli M, Lindsey MA. Patterns of healthcare discrimination among transgender help-seekers. *Am J Prev Med*. 2020;58(4):e123-e131. doi.org/10.1016/j.amepre.2019.11.002
9. Uhrig JD, Stryker JE, Bresee S, et al. HIV information needs of transgender people and their healthcare providers. *AIDS Care*. 2019;31(3):357-363. doi.org/10.1080/09540121.2018.1499862
10. Warner DM, Mehta AH. Identifying and addressing barriers to transgender healthcare: where we are and what we need to do about it. *J Gen Intern Med*. 2021;36(11):3559-3561. [doi: 10.1007/s11606-021-07001-2](https://doi.org/10.1007/s11606-021-07001-2)

3.2 HCP perspective

1. Chen D, Kolbuck VD, Sutter ME, et al. Knowledge, practice behaviors, and perceived barriers to fertility care among providers of transgender healthcare. *J Adolesc Health*. 2019;64(2):226-234. [DOI: 10.1016/j.jadohealth.2018.08.025](https://doi.org/10.1016/j.jadohealth.2018.08.025)
2. Dutton S, Cimino AN, Lombardo MJ, et al. Assessing knowledge, attitudes and beliefs of nurses about LGBTQ older adults using a documentary video. *Nurse Educ*. 2022;108:105177. <https://doi.org/10.1016/j.nedt.2021.105177>

3. Eickhoff C. Identifying gaps in LGBTQ health education in baccalaureate undergraduate nursing programs. *J Nurs Educ.* 2021;60(10):552-558. <https://doi.org/10.3928/01484834-20210729-01>
4. Greene MZ, France K, Kreider EF, et al. Comparing medical, dental, and nursing students' preparedness to address lesbian, gay, bisexual, transgender, and queer health. *PloS One.* 2018;13(9):e0204104. [DOI: 10.1371/journal.pone.0204104](https://doi.org/10.1371/journal.pone.0204104)
5. Guerrero-Hall KD, Muscanell R, Garg N, et al. Obstetrics and gynecology resident physician experiences with lesbian, gay, bisexual, transgender and queer healthcare training. *Med Sci Educ.* 2021;31(2):599-606. [DOI: 10.1007/s40670-021-01227-9](https://doi.org/10.1007/s40670-021-01227-9)
6. Levy A, Prasad S, Griffin DP, et al. Attitudes and knowledge of medical students towards healthcare for lesbian, gay, bisexual, and transgender seniors: impact of a case-based discussion with facilitators from the community. *Cureus.* 2021;13(8):e17425. [DOI: 10.7759/cureus.17425](https://doi.org/10.7759/cureus.17425)
7. Loo S, Almazan AN, Vedilago V, et al. Understanding community member and health care professional perspectives on gender-affirming care - a qualitative study. *PloS One.* 2021;16(8):e0255568. doi.org/10.1371/journal.pone.0255568
8. Shires DA, Prieto L, Woodford MR, et al. Gynecologic health care providers' willingness to provide routine care and Papanicolaou tests for transmasculine individuals. *J Women's Health.* 2019;28(11):1487-1492. [DOI: 10.1089/jwh.2018.7384](https://doi.org/10.1089/jwh.2018.7384)
9. Taneja A, Stark S, Chokshi B, et al. A knowledge, attitudes and practices survey for medical trainees about cancer in the LGBTQ community. *J Clin Oncol.* 2020;38(15):e19073. [DOI: 10.1200/JCO.2020.38.15_suppl.e19073](https://doi.org/10.1200/JCO.2020.38.15_suppl.e19073)
10. VanDerKolk K, McKinney V, Graves L, et al. Transgender education in North American family medicine clerkships: a CERA study. *Fam Med.* 2021;53(8):676-683. [DOI: 10.22454/FamMed.2021.509974](https://doi.org/10.22454/FamMed.2021.509974)

3.3 Existing strategies

1. Crapanzano A, Mixon L. The state of affirmative mental health care for transgender and gender non-confirming people: an analysis of current research, debates, and standards of care. *Riv Psichiatr.* 2022;57(1):44-54. [doi 10.1708/3749.37327](https://doi.org/10.1708/3749.37327)
2. Medina-Martínez J, Saus-Ortega C, Sánchez-Lorente MM, et al. Health inequities in LGBT people and nursing interventions to reduce them: a systematic review. *Int J Environ.* 2021;18(22):11801. doi.org/10.3390/ijerph182211801
3. Ziegler E, Luctkar-Flude M, Carroll B, et al. Development of an online educational toolkit for sexual orientation and gender identity minority nursing care. *Rev Lat Am Enfermagem.* 2021;29:e3470. doi.org/10.1590/1518-8345.4712.3470
4. Klein A, Golub SA. Enhancing gender-affirming provider communication to increase health care access and utilization among transgender men and trans-masculine non-binary individuals. *LGBT Health.* 2020;7(6):292-304. doi.org/10.1089/lgbt.2019.0294
5. Grundmann O, Segal R, Pullo J, et al. The pharmacist as an LGBTQ ally. *Am J Pharm Educ.* 2020;84(7):ajpe7835. doi.org/10.5688/ajpe7835
6. Ding JM, Ehrenfeld JM, Edmiston EK, et al. A model for improving health care quality for transgender and gender nonconforming patients. *Jt Comm J Qual Patient Saf.* 2020;46(1):37-43. doi.org/10.1016/j.jcjq.2019.09.005
7. Stryker SD, Pallerla H, Pickle S. Considerations on medical training for gender-affirming care: motivations and perspectives. *Int J Trans Health.* 2019;21(1):79-88. <https://doi.org/10.1080/15532739.2019.1689880>

8. Stevenson MO, Sineath RC, Haw JS, et al. Use of standardized patients in endocrinology fellowship programs to teach competent transgender care. *J Endo Soc.* 2019;4(1):bvz007. <https://doi.org/10.1210/jendso/bvz007>
9. Jadwin-Cakmak L, Reisner SL, Hughto JMW, et al. HIV prevention and HIV care among transgender and gender diverse youth: design and implementation of a multisite mixed-methods study protocol in the U.S. *BMC Public Health.* 2019;19(1):1531. DOI: [10.1186/s12889-019-7605-4](https://doi.org/10.1186/s12889-019-7605-4)
10. Klein P, Narasimhan S, Safer JD. The Boston Medical Center experience: an achievable model for the delivery of transgender medical care at an academic medical center. *Trans Health.* 2018;3(1):136-140. <https://doi.org/10.1089/trgh.2017.0054>

4. Guidelines to improve inclusivity for transgender and non-binary patients in clinical research

1. Blotner C, Rajunov M. Engaging transgender patients: using social media to inform medical practice and research in transgender health. *Transgender Health.* 2018;3(1):225-228. doi.org/10.1089/trgh.2017.0039
2. Chen B, Jin H, Yang Z, et al. An approach for transgender population information extraction and summarization from clinical trial text. *BMC Medical Inform.* 2019;19(suppl 2):62. doi.org/10.1186/s12911-019-0768-1
3. Jones NC, Reyes ME, Quinn GP, et al. Survey of principal investigators in biobanking: knowledge, attitudes, and research behaviors about transgender and gender-diverse patients. *JCO Oncol Pract.* 2020;16(10):e1192-e1201. doi.org/10.1200/OP.20.00193
4. Moseson H, Zazanis N, Goldberg E, et al. The imperative for transgender and gender nonbinary inclusion: beyond women's health. *Obstet Gynecol.* 2020;135(5):1059-1068. doi.org/10.1097/AOG.0000000000003816
5. Smith TM. American Medical Association. Why IRBs must scrutinize collection of LGBTQ information. 2020. Available at: <https://www.ama-assn.org/delivering-care/population-care/why-irbs-must-scrutinize-collection-lgbtq-information>. Accessed May 12, 2022.
6. Staples JM, Bird ER, Masters TN, et al. Considerations for culturally sensitive research with transgender adults: a qualitative analysis. *J Sex Res.* 2018;55(8):1065-1076. doi.org/10.1080/00224499.2017.1292419

5. Additional reading

1. National Academies of Sciences, Engineering, and Medicine. 2022. Measuring Sex, Gender Identity, and Sexual Orientation. Washington, DC: The National Academies Press. <https://doi.org/10.17226/26424>